Page last updated: 2024-09-02

3-deoxyglucosone and Albuminuria

3-deoxyglucosone has been researched along with Albuminuria in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Hanssen, NMJ; Hovind, P; Parving, HH; Persson, F; Piazza, M; Rossing, P; Schalkwijk, CG; Scheijen, JL; Stehouwer, CDA; van de Waarenburg, MPH; van Greevenbroek, MMJ	1

Trials

1 trial(s) available for 3-deoxyglucosone and Albuminuria

Article	Year
Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study. Diabetic medicine : a journal of the British Diabetic Association, 2021, Volume: 38, Issue:9 Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Chromatography, Liquid; Deoxyglucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Glyoxal; Humans; Irbesartan; Male; Middle Aged; Pyruvaldehyde; Tandem Mass Spectrometry; Time Factors; Treatment Outcome	2021

Article

Year

Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study.

Diabetic medicine : a journal of the British Diabetic Association, 2021, Volume: 38, Issue:9

Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Chromatography, Liquid; Deoxyglucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Glyoxal; Humans; Irbesartan; Male; Middle Aged; Pyruvaldehyde; Tandem Mass Spectrometry; Time Factors; Treatment Outcome

2021